Back to discover
Disease
Hyperaldosteronism
Late-stage therapeutic developmentEmerging research
1
Publications
9
Clinical trials
2024
Latest publication
Latest activity
betaRecent clinical, regulatory, research and industry developments relating to this disease.
Subclinical Primary Aldosteronism and Cardiovascular Health: A Population-Based Cohort Study.
Research2023-11-30Circulation
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
Executive briefingUpdating summary…Momentum: Low
Key developments
- 2 clinical trials expected to report results, the earliest in Q3 2027.
Upcoming Milestones
- Q3 2027A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy and Safety of Baxdrostat in Adult Participants With Primary Aldosteronism
- Q4 2027Phase 2 Study Evaluating the Functional Status of the Adrenal Glands With [68Ga]Ga-PentixaFor in Hyperaldosteronism and Hypercortisolism
Major developments
Upcoming trial readoutHigh impact
Results expected Q3 20272026-07-06
Upcoming trial readoutHigh impact
Results expected Q4 20272026-06-29
Clinical MilestonesViewHide
Results posted
Results expected
- 2026-07-06A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy and Safety of Baxdrostat in Adult Participants With Primary AldosteronismResults expected Q3 2027
- 2026-06-29Phase 2 Study Evaluating the Functional Status of the Adrenal Glands With [68Ga]Ga-PentixaFor in Hyperaldosteronism and HypercortisolismResults expected Q4 2027
Recently completed
Activity timeline4
- 2026-07-06ClinicalA Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy and Safety of Baxdrostat in Adult Participants With Primary AldosteronismResults expected Q3 2027
- 2026-06-29ClinicalPhase 2 Study Evaluating the Functional Status of the Adrenal Glands With [68Ga]Ga-PentixaFor in Hyperaldosteronism and HypercortisolismResults expected Q4 2027
- 2026-03-03ClinicalA Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, and Effectiveness of CIN-107 for the Management of Blood Pressure in Patients With Primary AldosteronismResults posted
- 2025-12-31ClinicalA Prospective Randomized Controlled Trial for Treatment of Idiopathic Hyperaldosteronism: Superselective Adrenal Arterial Embolization Versus Oral SpironolactonePrimary completion
Clinical trials
The current development programme across all trial phases.
Clinical programme
9
4
1
3
Recruiting
Recently completed
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Most influential
Major themes3
- Cardiovascular Diseases1
- Hyperaldosteronism1
- Hypertension1
Leading journals1
- Circulation1
Leading researchers8
- Agharazii M1
- Brown JM1
- Crean AM1
- Goupil R1
- Hametner B1
- Hiremath S1
- Hundemer GL1
- Kline GA1
Affiliations (unnormalised)6
- Brigham and Women's Hospital1
- Center for Adrenal Disorders1
- Center for Health & Bioresources1
- CHU de Québec-Université Laval1
- Clinical Epidemiology Program1
- Cumming School of Medicine1
Reference
Authoritative identity, definition & identifiers.
Defined in MeSH
A condition caused by the overproduction of ALDOSTERONE. It is characterized by sodium retention and potassium excretion with resultant HYPERTENSION and HYPOKALEMIA.
Identifiers
References & data sources
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.